← Back to Search

ASL-MRI for Kidney Cancer

N/A

Waitlist Available

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with locally advanced or metastatic renal cell carcinoma

Patients scheduled to undergo anti-angiogenic treatment or immunotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial will use MRI to track changes in the tumor before, during, and after treatment in up to 6 sessions, scheduled around the patient's clinical imaging sessions.

Who is the study for?

This trial is for adults with advanced or spreading kidney cancer who are about to start anti-angiogenic treatment or immunotherapy. They must be able to consent, not pregnant, and have an ECOG status of 0-2 (which measures their level of functioning). People can't join if they're on other anti-angiogenic drugs, pregnant, have MRI-incompatible devices in their body, severe allergies to Gadolinium contrast agents, certain blood disorders or conditions that make lying still for an MRI impossible.Check my eligibility

What is being tested?

The trial tests how well a type of MRI scan called Arterial Spin Labeling (ASL) can track changes in kidney tumors during treatment. Participants will undergo up to six additional MRIs over seven months plus standard follow-ups for three years. The ASL scans may show changes in tumor blood flow as early as two weeks after starting therapy.See study design

What are the potential side effects?

There are generally no side effects associated with undergoing an MRI itself; however, the process might be uncomfortable due to its duration and the need to remain still. There's also a small risk related to allergic reactions from any potential use of Gadolinium-based contrast agent.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney cancer has spread beyond the kidney.

Select...

I am scheduled for treatment that stops tumors from making new blood vessels or boosts my immune system.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in perfusion in the tumor

Progression Free Survival (PFS)

Secondary outcome measures

ASL measured perfusion within enhancing tumor

Overall Survival (OS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: RCC PatientsExperimental Treatment1 Intervention

Patients with locally advanced or metastatic renal cell carcinoma

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,050 Previous Clinical Trials

1,054,269 Total Patients Enrolled

Media Library

MRI with ASL Clinical Trial Eligibility Overview. Trial Name: NCT04831138 — N/A

Kidney Cancer Research Study Groups: RCC Patients

Kidney Cancer Clinical Trial 2023: MRI with ASL Highlights & Side Effects. Trial Name: NCT04831138 — N/A

MRI with ASL 2023 Treatment Timeline for Medical Study. Trial Name: NCT04831138 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study actively seeking participants at the moment?

"According to information posted on clinicaltrials.gov, this study is currently recruiting participants with the original post date being March 24th 2021 and most recent update occurring April 1st 2022."

Answered by AI

How many participants are included in this trial?

"Affirmative, the information on clinicaltrials.gov states that this research protocol is actively recruiting participants. First posted in March 2021 and last modified in April 2022, 90 individuals are required to participate at a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

Ananth Madhuranthakam 2021. "Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04831138.

All > Metastatic Renal Cell Carcinoma > Renal Cell Carcinoma